BPC-157
Pentadecapeptide studied for tissue protection and repair models.
Evidence Level
Moderate
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
Pentadecapeptide studied for tissue protection and repair models.
/ 02
Mechanism of Action
Studied for angiogenesis, growth factor modulation, and cytoprotection of gut/tendon tissue in animal models.
/ 03
Research Applications
Tendon, ligament, gut barrier, and inflammatory modulation research.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Animal studies report wide microgram-per-kilogram ranges; not approved for human use.
/ 06
Potential Adverse Effects Reported in Research
Human safety not established; not FDA approved.
/ 07
Mechanism Deep Dive
BPC-157 is a synthetic 15-amino-acid sequence derived from a portion of human gastric juice protein. Preclinical research investigates angiogenic signaling, fibroblast activity, nitric oxide pathway interactions, and growth factor expression relevant to soft-tissue repair models.
/ 08
Pathway Role
Positioned within the tissue repair and angiogenesis pathway, with reported activity at the vascular signaling and extracellular matrix interface in animal models.
/ 09
Biological Targets
/ 10
Research Applications
- Tendon and ligament injury models
- Gastrointestinal mucosal injury models
- Wound healing preclinical studies
- Vascular and angiogenesis research
/ 11
Evidence Summary
Evidence base is dominated by rodent studies and in vitro work. Public interest is high, but human-quality controlled trials are limited.
Evidence Level Rationale
Rated emerging-to-low because mechanistic preclinical evidence is broad but human controlled studies are scarce.
/ 12
Research Observation Timeline
Early Signal Window
Marker changes in cell and rodent studies within days
Primary Study Window
Experimental injury windows of days to several weeks in animal models
Endpoint Type
Histological and biomarker repair endpoints
Evidence Strength
Preclinical, limited human data
/ 13
Safety & Unknowns
Human safety profile is not well-characterized in published controlled studies. Long-term human outcomes are not established.
/ 14
Research Limitations
Most claims rest on animal injury models. Translation to human repair timelines is not supported by adequate clinical literature.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Moderate
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
TB-500
Thymosin Beta-4 fragment
Synthetic fragment studied for cell migration and tissue remodeling.
SS-31
Elamipretide
Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.
MOTS-c
Mitochondrial-derived peptide studied in AMPK signaling research.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.